LGND Q4 2020 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$70M+159.2% YoY

Gross Profit

$58M83.2% margin

Operating Income

$11M16.0% margin

Net Income

$6M8.2% margin

EPS (Diluted)

$0.35

QoQ Revenue Growth

+67.2%

Cash Flow

Operating Cash Flow

$537,000

Free Cash Flow

-$4M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$653M

Stockholders' Equity

$710M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$70M	$27M	+159.2%
Gross Profit	$58M	$25M	+132.4%
Operating Income	$11M	-$10M	+210.1%
Net Income	$6M	-$7M	+178.2%

Revenue Segments

Material Sales, Captisol

$87M61%

Contract Revenue

$26M18%

Service

$14M10%

Milestone

$11M7%

License Fees

$4M3%